SCHEMBL25645369

SCHEMBL25645369

C#CN1C(=O)S/C(=C/c2ccc(CC)cc2)C1=O

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MYC P01106 7/20 0.68
▸ MAX P61244 6/20 0.68
▸ IGF1R P08069 1/20 0.51
▸ PIM1 P11309 1/20 0.51
▸ PIM2 Q9P1W9 1/20 0.51
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ AURKA O14965 2/20 0.44
▸ CISD1 Q9NZ45 3/20 0.43
▸ PPARG P37231 1/20 0.43
▸ MAOA P21397 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ KDR P35968 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20816068 0.81 MYC (1.00) MYCMAXIGF1RPIM1PIM2
SCHEMBL20816069 0.81 MYC (1.00) MYCMAXIGF1RPIM1PIM2
SCHEMBL17934519 0.80 MYC (0.63) MYCMAXIGF1RPIM1PIM2
SCHEMBL17934604 0.76 MYC (0.59) MYCMAXIGF1RPIM1PIM2
SCHEMBL25645430 0.76 MYC (0.59) MYCMAXIGF1RPIM1PIM2
SCHEMBL17927322 0.74 MAPK1 (0.71) MYCMAXIGF1RPIM1PIM2
SCHEMBL17927320 0.74 MAPK1 (0.71) MYCMAXIGF1RPIM1PIM2
SCHEMBL17051283 0.70 MYC (0.76) MYCMAXNPC1RAB9AMEN1
SCHEMBL17927286 0.69 MYC (0.60) MYCMAXIGF1RPIM1PIM2
SCHEMBL31376923 0.69 MYC (0.68) MYCMAXNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212568-A1 MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS UNIVERSITY OF ROCHESTER 2023-07-06 — — US disclosed
US-20230190961-A1 COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY BY REJUVENATING GLIAL PROGENITOR CELLS UNIVERSITY OF ROCHESTER 2023-06-22 — — US disclosed
US-20230133695-A1 METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS UNIVERSITY OF ROCHESTER 2023-05-04 — — US disclosed
US-20230133695-A1 METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS UNIVERSITY OF ROCHESTER 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133695-A1 METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS IKZF3, IKZF1, CXXC4 MYC 19/4885MAX 558/4885IGF1R 1262/4885
US-20230190961-A1 COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY BY REJUVENATING GLIAL PROGENITOR CELLS TEAD2, MYT1, TEAD1 MYC 32/4885MAX 2012/4885IGF1R 4674/4885
US-20230212568-A1 MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS MYT1, STAT3, MYC MYC 3/4885MAX 747/4885IGF1R 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback